Literature DB >> 16869761

Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors.

L Zender1, W Xue, C Cordón-Cardo, G J Hannon, R Lucito, S Powers, P Flemming, M S Spector, S W Lowe.   

Abstract

Hepatocellular carcinoma is a chemoresistant cancer and a leading cause of cancer mortality; however, the molecular mechanisms responsible for the aggressive nature of this disease are poorly understood. In this study, we developed a new liver cancer mouse model that is based on the ex vivo genetic manipulation of embryonic liver progenitor cells (hepatoblasts). After retroviral gene transfer of oncogenes or short hairpin RNAs targeting tumor suppressor genes, genetically altered liver progenitor cells are seeded into the liver of otherwise normal recipient mice. We show that histopathology of the engineered liver carcinomas reveals features of the human disease. Furthermore, representational oligonucleotide microarray analysis (ROMA) of murine liver tumors initiated by two defined genetic hits revealed spontaneously acquired genetic alterations that are characteristic for human hepatocellular carcinoma. This model provides a powerful platform for applications like cancer gene discovery or high-throughput preclinical drug testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869761      PMCID: PMC4595853          DOI: 10.1101/sqb.2005.70.059

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  56 in total

1.  Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis.

Authors:  T I Huo; X W Wang; M Forgues; C G Wu; E A Spillare; C Giannini; C Brechot; C C Harris
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

2.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

Review 3.  Genetics of hepatocellular carcinoma.

Authors:  M A Buendia
Journal:  Semin Cancer Biol       Date:  2000-06       Impact factor: 15.707

4.  Growth in culture and tumorigenicity after transfection with the ras oncogene of liver epithelial cells from carcinogen-treated rats.

Authors:  L Braun; M Goyette; P Yaswen; N L Thompson; N Fausto
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

5.  The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma.

Authors:  Brian C Lewis; David S Klimstra; Nicholas D Socci; Su Xu; Jason A Koutcher; Harold E Varmus
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

6.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation.

Authors:  J T Nhieu; C A Renard; Y Wei; D Cherqui; E S Zafrani; M A Buendia
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

7.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; T Komeda; R Kita; T Sando; M Furukawa; M Amenomori; I Shibagaki; K Nakao; M Ikenaga
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

8.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

9.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.

Authors:  H Murakami; N D Sanderson; P Nagy; P A Marino; G Merlino; S S Thorgeirsson
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

10.  Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium.

Authors:  G D Block; J Locker; W C Bowen; B E Petersen; S Katyal; S C Strom; T Riley; T A Howard; G K Michalopoulos
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

View more
  35 in total

Review 1.  Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.

Authors:  Tim F Greten; Xin W Wang; Firouzeh Korangy
Journal:  Gut       Date:  2015-02-09       Impact factor: 23.059

2.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas.

Authors:  Wen Xue; Lars Zender; Cornelius Miething; Ross A Dickins; Eva Hernando; Valery Krizhanovsky; Carlos Cordon-Cardo; Scott W Lowe
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

3.  Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.

Authors:  Kate Revill; Tim Wang; Anja Lachenmayer; Kensuke Kojima; Andrew Harrington; Jinyu Li; Yujin Hoshida; Josep M Llovet; Scott Powers
Journal:  Gastroenterology       Date:  2013-09-05       Impact factor: 22.682

Review 4.  In vivo RNAi screens: concepts and applications.

Authors:  Shane Crotty; Matthew E Pipkin
Journal:  Trends Immunol       Date:  2015-04-27       Impact factor: 16.687

Review 5.  Cancer gene discovery in hepatocellular carcinoma.

Authors:  Lars Zender; Augusto Villanueva; Victoria Tovar; Daniela Sia; Derek Y Chiang; Josep M Llovet
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

6.  Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.

Authors:  Tamar Kapanadze; Jaba Gamrekelashvili; Chi Ma; Carmen Chan; Fei Zhao; Stephen Hewitt; Lars Zender; Veena Kapoor; Dean W Felsher; Michael P Manns; Firouzeh Korangy; Tim F Greten
Journal:  J Hepatol       Date:  2013-06-22       Impact factor: 25.083

7.  Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target.

Authors:  Anna Saborowski; Michael Saborowski; Monika A Davare; Brian J Druker; David S Klimstra; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-23       Impact factor: 11.205

8.  A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer.

Authors:  Kathryn A O'Donnell; Vincent W Keng; Brian York; Erin L Reineke; Daekwan Seo; Danhua Fan; Kevin A T Silverstein; Christina T Schrum; Wei Rose Xie; Loris Mularoni; Sarah J Wheelan; Michael S Torbenson; Bert W O'Malley; David A Largaespada; Jef D Boeke
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-03       Impact factor: 11.205

9.  IDH mutations in liver cell plasticity and biliary cancer.

Authors:  Supriya K Saha; Christine A Parachoniak; Nabeel Bardeesy
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Modeling pathogenesis of primary liver cancer in lineage-specific mouse cell types.

Authors:  Ágnes Holczbauer; Valentina M Factor; Jesper B Andersen; Jens U Marquardt; David E Kleiner; Chiara Raggi; Mitsuteru Kitade; Daekwan Seo; Hirofumi Akita; Marian E Durkin; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2013-03-19       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.